Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States

Journal of Medical Economics
Alison T StopeckGuy Hechmati

Abstract

Aims: Bone complications (also known as skeletal-related events [SREs]) pose significant health and financial burdens on patients with bone metastases. Denosumab demonstrated superiority over zoledronic acid in delaying the time to first SRE. This study examined the lifetime cost-effectiveness of denosumab vs zoledronic acid from both US payer and societal perspectives. Methods: This analysis used a lifetime Markov model and included patients with breast cancer, prostate cancer, and other solid tumors and bone metastases. The societal perspective included direct medical, direct non-medical, and indirect costs associated with denosumab and zoledronic acid; the payer perspective included direct medical costs only. Bone complication rates for each tumor type were estimated from three pivotal phase 3 studies and modified to reflect real-world incidence. Results: From a societal perspective, compared with zoledronic acid, denosumab use resulted in an incremental cost of $9,043, an incremental benefit of 0.128 quality-adjusted life-years (QALYs), a lifetime cost per QALY of $70,730, and a net monetary benefit (NMB) of $10,135 in favor of denosumab. Direct drug costs for denosumab ($28,352) were higher than zoledronic acid/untreated (...Continue Reading

References

Oct 3, 2002·Journal of the National Cancer Institute·Fred SaadUNKNOWN Zoledronic Acid Prostate Cancer Study Group
Jul 30, 2003·Archives of Internal Medicine·Peter A UbelA Mark Fendrick
Oct 2, 2004·The Oncologist·Robert E Coleman
Feb 16, 2006·The Oncologist·Eric NadlerPeter J Neumann
Feb 21, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jean-Jacques BodyPirow J Bekker
Jul 29, 2006·Arthritis and Rheumatism·Michael C Y TanCarlo A Marra
Jun 5, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Cesare GridelliCristina Negrini
Jan 6, 2010·International Journal of Environmental Research and Public Health·Steven Simoens
Nov 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alison T StopeckAda Braun
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·David H HenryHoward Yeh
Sep 15, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Allan LiptonSusie Jun
Sep 25, 2012·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Roberta Ara, Allan Wailoo
Jan 29, 2013·The European Journal of Health Economics : HEPAC : Health Economics in Prevention and Care·Louis S MatzaJean-Jacques Body
Mar 23, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Kaitlin KooEdward Chow
Jul 26, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Gerry OsterJohn Edelsberg
Aug 27, 2013·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Roger von MoosKaren Chung
May 2, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R ColemanUNKNOWN ESMO Guidelines Working Group
Aug 28, 2014·The New England Journal of Medicine·Peter J NeumannMilton C Weinstein
Dec 24, 2014·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Donald L PatrickYi Qian
Feb 19, 2015·The New England Journal of Medicine·Sandra M SwainUNKNOWN CLEOPATRA Study Group
Mar 17, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Scott D RamseySean D Sullivan
Sep 4, 2015·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Roger von MoosYi Qian
Nov 5, 2015·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·C BeaucheminJ Lachaine
Nov 22, 2015·Expert Review of Pharmacoeconomics & Outcomes Research·Athanasios Dellis, Athanasios Papatsoris
Jan 1, 2013·Journal of Market Access & Health Policy·Erpur Adalsteinsson, Mondher Toumi
Dec 29, 2016·JAMA : the Journal of the American Medical Association·Andrew L HimelsteinCharles L Shapiro
Jan 26, 2017·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Yi QianRohini K Hernandez

❮ Previous
Next ❯

Citations

Nov 19, 2020·British Journal of Cancer·Thomas H BeckhamC Jillian Tsai
Jun 3, 2021·Expert Opinion on Pharmacotherapy·Mohamad MoussaLazaros Tzelves
May 29, 2021·Clinical Breast Cancer·Charles L Shapiro
Jun 17, 2021·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·Tilman D RachnerLorenz C Hofbauer
Jul 31, 2021·Journal of Medical Economics·Javier Garcia PerlazaDavid Garcia

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.